Pharmacologic effect of recombinant human IFN-α, continuously released from a matrix prepared from a polyglycerol ester of fatty acids, on 2',5'- oligoadenylate synthetase activity in murine liver

Journal of Interferon and Cytokine Research

Volumn 20, Issue 2, 2000, Pages 153-160

  Yamagata, Yutaka ^a   Yuasa, Yumi ^a   Yamamoto, Kazumichi ^a   Okamoto, Kayoko ^a   Igari, Yasutaka ^a   Iga, Katsumi ^a   Ogawa, Yasuaki ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; FATTY ACID; GLYCEROL DERIVATIVE; RECOMBINANT ALPHA2A INTERFERON;

ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; DRUG EFFECT; ENZYME ACTIVITY; IMMUNOREGULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS INFECTION;

2',5'-OLIGOADENYLATE SYNTHETASE; ANIMALS; DELAYED-ACTION PREPARATIONS; DRUG IMPLANTS; GLYCEROL; HUMANS; INTERFERON ALFA-2A; KINETICS; LIVER; MALE; MICE; MICE, INBRED C3H; POLYMERS;

ANIMALIA; MURINAE;

EID: 0033998002     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/107999000312559     Document Type: Article

References (19)

1. 1. Pestka, S., Langer, J.A., Zoon, K.C., and Samuel, C.E. (1987). Interferons and their actions. Annu. Rev. Biochem. 56, 727-777.
2. 2. Perrillo, R.P. (1993). Interferon in the management of chronic hepatitis B. Dig. Dis. Sci. 38, 577-593.
3. 3. Poynard, T., Leroy, V., Cohard, M., Thevenot, T., Mathurin, P., Opolon, P., and Zarski, J.P. (1996). Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 24, 778-789.
4. 4. Carreno, V., Tapia, L., Ryff, J.-C., Quiroga J.A., and Castillo, I. (1992). Treatment of chronic hepatitis C by continuous subcutaneous infusion of interferon-alpha. J. Med. Virol. 37, 215-219.
5. 5. Schenker, S., Cultler, D., Finch, J., Tamburro, C.H., Affrime, M., Sabo, R., and Bay, M. (1997). Activity and tolerance of a continuous subcutaneous infusion of interferon-α2b in patients with chronic hepatitis C. J. Interferon Cytokine Res. 17, 665-670.
6. 6. Eppstein, D.A. (1982). Altered pharmacologic properties of liposome-associated human interferon-alpha. II. J. Interferon Res. 2, 117-125.
7. 7. Bonetti, A., and Kim, S. (1993). Pharmacokinetics of an extended-release human interferon alpha-2b formulation. Cancer Chemother. Pharmacol. 33, 258-261.
8. 8. Fujioka, K., Takada, Y., Sato, S., and Miyata, T. (1995). Novel delivery system for proteins using collagen as a carrier material: the minipellet. J. Control Release 33, 307-315.
9. 9. Fujioka K., Takada, Y., Sato, S., and Miyata, T. (1995). Long-acting delivery system of interferon: IFN minipellet. J. Control Release 33, 317-323.
10. 10. Yamagata, Y., Yamamoto, K., Okamoto, K., Iga, K., and Ogawa, Y. (1996). Novel prolonged-release dosage form of interferon-α using polyglycerol ester of fatty acid. Proc. Int. Symp. Control Release Bioact. Mater. 23, 15-16.
11. 11. Hughes, H.P.A., Rossow, S., Campos, M., Rossi-Campos, A., Janessen, S., Godson, D.L., Daflon, B., Voirol, M.J., Gerber, C., and Babiuk, L.A. (1994). A slow release formulation for recombinant bovine interferon αI-1. Antiviral Res. 23, 33-44.
12. 12. Baglioni, C. (1979). Interferon-induced enzymatic activities and their role in the antiviral state. Cell 17, 255-264.
13. 13. Lengyel, P. (1981). Mechanisms of interferon action: the (2′-5′)(A)n synthetase-RNase L pathway. In: Interferon 3. J.I. Gresser, ed. New York: Academic Press, pp. 77-99.
14. 14. Nishiguchi, S., Kuroki, T., Otani, S., Takada, T., Hirota, S., Shimizu, Y., Nakajima, S., Saito, S., Shiomi, S.L., and Kobayashi, K. (1989). Relationship of the effects of interferon on chronic hepatitis B and the induction of 2′,5′-oligoadenylate synthetase. Hepatology 10, 29-33.
15. 15. Furuta, M., Akashi, K., Nakamura, Y., Matsumoto, K., Yamaguchi, H., Takamatsu, S., and Shimizu, T. (1987). 2′,5′-Oligoadenylate synthetase activity in peripheral blood lymphocytes as a clinical marker in interferon therapy for chronic hepatitis B. J. Interferon Res. 7, 111-119.
16. 16. Shindo, M., Okuno, T., Matsumoto, M., Takeda, M., Takino, T., Sokawa, J., Iwata, A., and Sokawa, Y. (1988). Serum 2′,5′-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis B. Hepatology 8, 366-370.
17. 17. Weber, H., Valenzuela, D., Lujberg, G., Gubler,G., and Weissmann, C. (1987). Single amino acid changes that render human IFN-α2 biologically active on mouse cell. EMBO J. 6, 591-598.
18. 18. Lu, W., and Park, T.G. (1995). In vitro release profiles of eristostatin from biodegradable polymeric microspheres: protein aggregation problem. Biotechnol. Prog. 11, 224-227.
19. 19. Lu, W., and Park, T.G. (1995). Protein release from poly (lac-tic-co-glycolic acid) microspheres: protein stability problems. PDA J. Pharm. Sci. Tech. 49, 13-19.